the aid library

Ukraine crisis. Public health situation analysis: refugee-hosting countries

World Health Organization WHO, Regional Office of Europe (2022) CC

17 March 2022

Health in the Americas 2022: Overview of the Region of the Americas in the context of the COVID-19 pandemic

Pan American Health Organisation PAHO (2022) C_WHO

The objective of Health in the Americas: Overview of the Region of the Americas in the Context of the COVID-19 Pandemic is to respond to the need to address important public health issues in an increasingly timely manner, while serving as a platform with a close focus on specific issues of regional ... more

Report of a WHO–FIND meeting on diagnostics for Buruli ulcer

WHO Tecnical Advisory Group and FIND (2018) CC

The meeting was held from 26 to 27 March 2018 to review and discuss the following topics: Advances and challenges in the use of fTLC, and new approaches to detecting mycolactone using monoclonal antibodies (mAbs). The status of development of rapid diagnostic tests (RDTs) targeting the MUL... more

UNODC-WHO Stop-Overdose-Safely (‎S-O-S)‎ project implementation in Kazakhstan, Kyrgyzstan, Tajikistan and Ukraine

World Health Organization WHO; United Nations Office on Drugs and Crime UNODC (2021) C_WHO

Summary Report

Strengthening the Assessment of Lymphatic Filariasis Transmission and documenting the Achievement of Elimination

World Health Organization WHO (2014) C_WHO

Meeting of the Neglected Tropical Diseases Strategic and Technical Advisory Group’s Monitoring and Evaluation Subgroup on Disease-specific Indicators

The conflict in Ukraine and its impact on organized crime and security - November 2022

UN Interregional Crime and Justice Research Institute UNICRI Reliefweb OCHA Services (2022) C2

This report assesses the impact of the conflict in Ukraine and its implications for organized crime and security-related issues for neighbouring countries, with a focus on Moldova. These include: Organized crime and illicit trafficking (including trafficking in persons, drugs, arms, illicit toba... more

DNDi Strategic Plan 2021-2028 | DNDi - English version

DNDi - Drugs for neglected diseases initiative (2023) C2

Accessed on 04.04.2023 The Drugs for Neglected Diseases initiative (DNDi) is an international non-profit organization that discovers, develops, and delivers safe, effective, and affordable treatments for the most neglected patients

Ending the neglect to attain the sustainable development goals: a strategic framework for integrated control and management of skin-related neglected tropical diseases

World Health Organization WHO (2022) C_WHO

Skin-related neglected tropical diseases, or “skin NTDs”, are historically neglected because active case detection, individual case management, significant resources and intensive effort are required to control, eliminate and eradicate them. Integrated control and management of skin NTDs offers ... more

Mapping Antimicrobial Resistance and Antimicrobial Use Partnership (MAAP) Country Report Kenya

Africa Center for Disease Control and Prevention (2023) CC

The Mapping Antimicrobial Resistance and Antimicrobial Use Partnership (MAAP) project has conducted a multi-year, multi-country study that provides stark insights on the under-reported depth of the antimicrobial resistance (AMR) crisis across Africa and lays out urgent policy recommendations to addr... more

Step up the fight. Investment case

The Global Fund Reliefweb OCHA (2019) CC

Ending the epidemics of HIV, tuberculosis and malaria by 2030 is within reach, but not yet fully in our grasp. With only 11 years left, we have no time to waste. We must step up the fight now.

Therapeutics and COVID-19 (Living Guideline, 10 November 2023)

World Health Organization WHO (2023) C_WHO

WHO has updated its guidelines for COVID-19 therapeutics, with revised recommendations for patients with non-severe COVID-19. This is the 13th update to these guidelines. Updated risk rates for hospital admission in patients with non-severe COVID-19 The guidance includes updated risk rates for... hospital admission in patients with non-severe COVID-19. The current COVID-19 virus variants tend to cause less severe disease while immunity levels are higher due to vaccination, leading to lower risks of severe illness and death for most patients. This update includes new baseline risk estimates for hospital admission in patients with non-severe COVID-19. The new ‘moderate risk’ category now includes people previously considered to be high risk including older people and/or those with chronic conditions, disabilities, and comorbidities of chronic disease. The updated risk estimates will assist healthcare professionals to identify individuals at high, moderate or low risk of hospital admission, and to tailor treatment according to WHO guidelines: **High: **People who are immunosuppressed remain at higher risk if they contract COVID-19, with an estimated hospitalization rate of 6%. **Moderate: **People over 65 years old, those with conditions like obesity, diabetes and/or chronic conditions including chronic obstructive pulmonary disease, kidney or liver disease, cancer, people with disabilities and those with comorbidities of chronic disease are at moderate risk, with an estimated hospitalization rate of 3%. Low: Those who are not in the high or moderate risk categories are at low risk of hospitalization (0.5%). Most people are low risk. Review of COVID-19 treatments for people with non-severe COVID-19 WHO continues to strongly recommend nirmatrelvir-ritonavir (also known by its brand name ‘Paxlovid’) for people at high-risk and moderate risk of hospitalization. The recommendations state that nirmatrelvir-ritonavir is considered the best choice for most eligible patients, given its therapeutic benefits, ease of administration and fewer concerns about potential harms. Nirmatrelvir-ritonavir was first recommended by WHO in April 2022. If nirmatrelvir-ritonavir is not available to patients at high-risk of hospitalization, WHO suggests the use of molnupiravir or remdesivir instead. WHO suggests against the use of molnupiravir and remdesivir for patients at moderate risk, judging the potential harms to outweigh the limited benefits in patients at moderate risk of hospital admission. For people at low risk of hospitalization, WHO does not recommend any antiviral therapy. Symptoms like fever and pain can continue to be managed with analgesics like paracetamol. WHO also recommends against use of a new antiviral (VV116) for patients, except in clinical trials. The update also includes a strong recommendation against the use of ivermectin for patients with non-severe COVID-19. WHO continues to advise that in patients with severe or critical COVID-19, ivermectin should only be used in clinical trials. more

WHF Roadmap for Digital Health in Cardiology

Tromp, J.; Jindal, D.; Redfern, J. et al. Global Heart (2022) CC

ABSTRACT More than 500 million people worldwide live with cardiovascular disease (CVD). Health systems today face fundamental challenges in delivering optimal care due to ageing populations, healthcare workforce constraints, financing, availability and affordability of CVD medicine, and service del... more

WHO operational handbook on tuberculosis Module 1: prevention - tuberculosis preventive treatment, second edition

World Health Organisation (WHO) (2024) C_WHO

About one fourth of the world’s population is estimated to have been infected with the tuberculosis (TB) bacilli, and about 5–10% of those infected develop TB disease in their lifetime. The risk for TB disease after infection depends on several factors, the most important being the person’s im... more

Лечение наркомании и реабилитация: практическое руководство по планированию и осуществлению

United Nations Office on Drugs and Crime (2003) CC

Мы предлагаем вам ознакомиться с практическим руководством Программы Организации Объединенных Наций по международному контролю над наркотиками (ЮНДКП) по планир... more

Расширение доступности психотропных средств и улучшение практики их использования

Michelle Funk, José Miguel Caldas de Almeida, Natalie Drew et al. World Health Organization (2007) C_WHO

Свод методических рекомендаций состоит из нескольких тематически связанных и удобных для пользователя модулей для решения широкого спектра задач и приоритетных ... more

Antibiotic use and resistance in South Africa

Dr T Apalata, Dr C Bamford, Mr D Benjamin et al. South African Medical Journey SAMJ (2011) C2

Antimicrobial resistance (AMR) is an important public health concern shared by developed and developing countries. In developing countries the burden of infectious diseases is greater and exacerbated by limited access to, and availability and affordability of, antimicrobials required to treat infect... more

Thailand's National Strategic Plan on Antimicrobial Resistance 2017-2021

Ministery of Public Health, Thailand (2017) C1

Situation Analysis: Antibiotic use and resistance in South Africa

The Center for Disease Dynamics, Economics & Policy CDDEP (2011) C2

South Africa has faced many challenges over the past two decades, accomplishing profound positive changes in the social structure and government of the nation. This has not yet fully translated into better health for the population, however, particularly the poorest segment. In fact, the p... more

International instruments on the use of antimicrobials across the human, animal and plant sectors

the Food and Agriculture Organization of the United Nations (FAO), the World Organisation for Animal Health (OIE) and the World Health Organization (WHO) (2020) C_WHO

The publication provides an overview and analysis of international instruments that set standards related to the use of antimicrobials across the human, animal and plant sectors, and their release into the environment. The purpose of the document is to identify existing instruments and standards in ... more